



ASX & Media Release

## Dr. Pamela M. Klein appointed as Patrys Non-Executive Director

**Melbourne, Australia; 1 October 2019:** Patrys Limited (ASX: PAB, "Patrys" or the Company), a therapeutic antibody development company, is pleased to announce the appointment of Dr. Pamela M. Klein as Non-Executive Director of Patrys.

### Key highlights

- Appointment of Dr. Pamela M. Klein as Non-Executive Director of Patrys, an experienced US-based oncology biotech executive with over 20 years of experience
- Dr. Klein currently holds advisory and corporate board roles for various biotech and investment companies and has significant clinical development expertise
- Dr. Klein has a proven track record in clinical and commercial development and brings a wealth of knowledge and industry expertise to Patrys

**Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said:** *"Dr. Klein has been an integral member of the Patrys Scientific Advisory Board for over two years and we are proud to announce that she is joining our Board as a Non-Executive Director. Dr. Klein has a proven track record in both the clinical and commercial aspects of oncology. Her extensive commercial, clinical and regulatory experience will enhance the Board's expertise as we progress the development of PAT-DX1 towards the clinic, and the broader commercialisation of the Deoxymab platform."*

Dr. Klein has a proven track record as an executive over more than 20 years in the oncology and biopharmaceutical industry. Dr. Klein initially joined Patrys' Scientific Advisory Board in 2017 and her significant industry experience will provide the Company with valuable knowledge and support as Patrys prepares for an IND filing at the end of CY2020.

**Dr. Klein said:** *I am thrilled to join the Patrys Board at this pivotal point in the Company's development. PAT-DX1's novel mechanism of action and its ability to cross the blood brain barrier creates significant opportunity to improve patient outcomes and I am looking forward to supporting the execution of the Company's development program."*

Dr. Klein is currently on the Board of Directors for Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in the areas of cancer and severe autoimmune disease. She is also on the Board of Spring Bank Pharmaceuticals (NASDAQ), a clinical stage biopharmaceutical company developing therapeutics for both HBV and oncology. Dr. Klein is the Principal and Founder of PMK BioResearch, which offers strategic consulting in oncology drug development.

Formerly, Dr. Klein was the Chief Medical Officer of Intellikine, where she built the clinical and regulatory infrastructure to bring multiple early compounds from laboratory to clinical development. Intellikine was acquired by Takeda in December 2011 for US\$300m. Prior to her role at Intellikine, Dr.



Klein held the role of Vice President, Development at Genentech where she led the development of a large portfolio of drugs including the Human Epidermal Receptor: HER (Herceptin, Tarceva, Perjeta), Apoptosis and Hematology compounds including Rituxan. Several of these, such as Herceptin and Rituxan became the foundation for the new standard of care for HER2+ breast cancer and numerous hematologic malignancies/autoimmune diseases respectively.

Dr. Klein completed her medical training at Stritch School of Medicine, Loyola University in Chicago, followed by internal medicine training at Cedars-Sinai, Los Angeles and oncology fellowship at the U.S. National Cancer Institute of the National Institute of Health.

As part of Dr Klein's Non-Executive Director agreement and remuneration package, she will be issued with a total of 4,000,000 unlisted options in the Company, exercisable at \$0.035 (3.5 cents) each, expiring 5 years from the date of grant, vesting as follows:

- 2,000,000 options vesting immediately at grant
- 1,000,000 options vesting on 1 October 2020 and the share price is equal to or greater than a 20 day VWAP of 5.0 cents
- 1,000,000 options vesting on 1 October 2021 and the share price is equal to or greater than a 20 day VWAP of 7.0 cents

**-Ends-**

To learn more please visit: [www.patrys.com](http://www.patrys.com).

**For further information, please contact:**

**General enquiries**

James Campbell  
Chief Executive Officer  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

**Media enquiries:**

Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

**About Patrys' Deoxymab 3E10 platform – lead candidates PAT-DX1 and PAT-DX1-NP:**

Patrys is a drug development company focused on commercialising antibody therapies for oncology. Patrys has exclusive worldwide rights to develop and commercialise the Deoxymab platform technology developed at Yale University (PAT-DX1, PAT-DX1-NP and 5C6) to form a portfolio of novel anti-cancer and diagnostic agents.

The Company's lead candidate, PAT-DX1 and its nanoparticle conjugated form (PAT-DX1-NP) have demonstrated significant potential as novel cancer therapy that has the capacity to cross the blood brain barrier, penetrate cancer cell nuclei, inhibit DNA repair and kill DNA repair-deficient cancer cells. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to significantly improve survival in orthotopic models of both triple negative breast cancer brain metastases and glioblastoma. PAT-DX1 has also been shown to enhance the therapeutic effect of low dose radiation. These characteristics open up new avenues for cancers including (but not limited to) breast, brain metastases, brain gliomas, pancreatic cancer, ovarian and prostate.